Literature DB >> 30069734

[Drugs for intravenous induction of anesthesia: ketamine, midazolam and synopsis of current hypnotics].

E Halbeck1, C Dumps2, D Bolkenius2.   

Abstract

Ketamine and midazolam form the endpoint of a series of articles about intravenous induction of anesthesia . Both substances can be used as single induction hypnotic drugs; however, in practice, this is unusual. Both substances, with the exception of a few very specific indications and clinical situations, are more frequently used in combination or with one of the more common alternatives propofol, barbiturates and etomidate. The reasons are the activity and side effects of both substances and their positive characteristics are used more as a supplement. In the concluding comparison the five discussed induction hypnotics are judged against each other. The use in certain clinical constellations and in special patient populations is evaluated individually for each substance. It is highlighted which drug appears most appropriate in which situation. As methohexital is nowadays only administered in very few clinical situations, this substance is not included in the comparative assessment.

Entities:  

Keywords:  Anesthetic drugs; Induction hypnotics; Pharmacodynamics; Pharmacokinetics; Sedatives

Mesh:

Substances:

Year:  2018        PMID: 30069734     DOI: 10.1007/s00101-018-0469-7

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  74 in total

1.  Happy 50th anniversary ketamine.

Authors:  Frederic Dorandeu
Journal:  CNS Neurosci Ther       Date:  2013-06       Impact factor: 5.243

Review 2.  [The clinical use of S-(+)-ketamine--a determination of its place].

Authors:  S Himmelseher; E Pfenninger
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  1998-12       Impact factor: 0.698

Review 3.  [Premedication with midazolam: indispensable and good?].

Authors:  A Machotta; G Schneider
Journal:  Anaesthesist       Date:  2013-03       Impact factor: 1.041

Review 4.  The Role of GABA Receptor Agonists in Anesthesia and Sedation.

Authors:  Janette Brohan; Basavana G Goudra
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

5.  Microglial Ca(2+)-activated K(+) channels are possible molecular targets for the analgesic effects of S-ketamine on neuropathic pain.

Authors:  Yoshinori Hayashi; Kodai Kawaji; Li Sun; Xinwen Zhang; Kiyoshi Koyano; Takeshi Yokoyama; Shinichi Kohsaka; Kazuhide Inoue; Hiroshi Nakanishi
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 6.  [Neuroprotection by ketamine at the cellular level].

Authors:  E Pfenninger; S Himmelseher
Journal:  Anaesthesist       Date:  1997-03       Impact factor: 1.041

7.  [Pharmacokinetics of midazolam in man (author's transl)].

Authors:  P M Lauven; H Stoeckel; H Ochs; D J Greenblatt
Journal:  Anaesthesist       Date:  1981-06       Impact factor: 1.041

Review 8.  Propofol.

Authors:  C Vanlersberghe; F Camu
Journal:  Handb Exp Pharmacol       Date:  2008

Review 9.  The pharmacology of propofol.

Authors:  M A Skues; C Prys-Roberts
Journal:  J Clin Anesth       Date:  1989       Impact factor: 9.452

10.  Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug.

Authors:  Filippia Aroni; Nicoletta Iacovidou; Ismene Dontas; Chryssa Pourzitaki; Theodoros Xanthos
Journal:  J Clin Pharmacol       Date:  2009-06-22       Impact factor: 3.126

View more
  2 in total

1.  [67-year-old male in resuscitation room for treatment after traffic accident : Preparation for the medical specialist examination: Part 7].

Authors:  C Dumps; D Bolkenius
Journal:  Anaesthesist       Date:  2019-04       Impact factor: 1.041

2.  Midazolam impacts acetyl-And butyrylcholinesterase genes: An epigenetic explanation for postoperative delirium?

Authors:  Katharina Rump; Caroline Holtkamp; Lars Bergmann; Hartmuth Nowak; Matthias Unterberg; Jennifer Orlowski; Patrick Thon; Zainab Bazzi; Maha Bazzi; Michael Adamzik; Björn Koos; Tim Rahmel
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.